Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT04519879Phase 2Suspended
Phase 2, randomised, open-label trial in prostate cancer (PCa) (4 arms), sponsored by City of Hope. Primary endpoints: Prostate-specific antigen levels at 12 weeks and Relative change in Prostate-specific antigen at 48 weeks. Started May 2021; status: suspended.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT04519879.